Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 26.5% in April

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 5,970,000 shares, a decline of 26.5% from the March 31st total of 8,120,000 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is presently 3.2 days.

Takeda Pharmaceutical Trading Down 0.3 %

Shares of NYSE:TAK traded down $0.04 during midday trading on Friday, reaching $13.03. The company's stock had a trading volume of 1,213,476 shares, compared to its average volume of 1,688,482. Takeda Pharmaceutical has a fifty-two week low of $13.01 and a fifty-two week high of $17.11. The firm has a market capitalization of $41.24 billion, a price-to-earnings ratio of 19.74, a PEG ratio of 2.98 and a beta of 0.53. The firm has a 50 day moving average price of $14.06 and a two-hundred day moving average price of $14.19. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The business had revenue of $7.52 billion during the quarter. As a group, analysts forecast that Takeda Pharmaceutical will post 1.5 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Rise Advisors LLC bought a new stake in Takeda Pharmaceutical in the 1st quarter valued at about $26,000. GAMMA Investing LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $28,000. Principal Securities Inc. bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $28,000. First United Bank & Trust bought a new stake in Takeda Pharmaceutical during the 4th quarter worth approximately $29,000. Finally, Lindbrook Capital LLC increased its holdings in Takeda Pharmaceutical by 40.6% during the 4th quarter. Lindbrook Capital LLC now owns 4,065 shares of the company's stock worth $58,000 after purchasing an additional 1,174 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.